TY - JOUR
T1 - Progesterone receptor gene polymorphisms and risk of endometriosis
T2 - Results from an international collaborative effort
AU - Near, Aimee M.
AU - Wu, Anna H.
AU - Templeman, Claire
AU - Van Den Berg, David J.
AU - Doherty, Jennifer A.
AU - Rossing, Mary Anne
AU - Goode, Ellen L.
AU - Cunningham, Julie M.
AU - Vierkant, Robert A.
AU - Fridley, Brooke L.
AU - Chenevix-Trench, Georgia
AU - Webb, Penelope M.
AU - Kjær, Susanne Krüger
AU - Hogdall, Estrid
AU - Gayther, Simon A.
AU - Ramus, Susan J.
AU - Menon, Usha
AU - Gentry-Maharaj, Aleksandra
AU - Schildkraut, Joellen M.
AU - Moorman, Patricia G.
AU - Palmieri, Rachel T.
AU - Ness, Roberta B.
AU - Moysich, Kirsten
AU - Cramer, Daniel W.
AU - Terry, Kathryn L.
AU - Vitonis, Allison F.
AU - Pike, Malcolm C.
AU - Berchuck, Andrew
AU - Pearce, Celeste Leigh
N1 - Funding Information:
The Ovarian Cancer Association Consortium is funded by the Ovarian Cancer Research Fund . Financial support was provided by U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729 , the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study) , and the National Health and Medical Research Council (NHMRC) of Australia ( 199600 ) (ACS study). G.C.-T. and P.M.W. are supported by the NHMRC . The Hormones and Ovarian Cancer Prediction Study of Delaware Valley study was supported by grants from the Department of Defense DAMD 17-02-1-0669 and the US National Cancer Institute RO1CA095023 . The work undertaken at Mayo is supported by R01-CA122443. The New England–based Case-Control Study was supported by the US National Cancer Institute grants RO1CA054419 and P50CA105009 . The work undertaken at University College London Hospital/University College London is supported by Cancer Research UK, Medical Research Council, The Eve Appeal, Oak Foundation , and the Department of Health's National Institute of Health Research Biomedical Research Centres funding scheme. The University of Southern California study was supported by the US National Cancer Institute grants P01-CA17054, CA14089, CA61132, CA63464, N01-PC67010, R03-CA113148 ; California Department of Health Services subcontract 050-E8709 ; and California Cancer Research Program grants 00-01389V-20170 and 2110200 .
Funding Information:
The AOCS Management Group (D. Bowtell, B.V.Sc (Hons), B.A.Sci., Ph.D., Georgia Chenevix-Trench, Ph.D., A. deFazio, Ph.D., D. Gertig, M.B.B.S., Ph.D., A. Green, M.B.B.S., Ph.D., Penelope M. Webb, Ph.D.) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see http://www.aocstudy.org/ ). The ACS Management Group comprises A. Green, M.B.B.S., Ph.D., P. Parsons, Ph.D., N. Hayward, Ph.D., Penelope M. Webb, Ph.D., and D. Whiteman, M.B.B.S., Ph.D. The authors are grateful to the family and friends of Kathryn Sladek Smith for their generous support of OCAC through their donations to the Ovarian Cancer Research Fund . The authors thank all the individuals who took part in these studies and the project staff of all the participating studies.
PY - 2011/1
Y1 - 2011/1
N2 - Objective: To investigate the association between self-reported endometriosis and the putative functional promoter +331C/T single nucleotide polymorphism and the PROGINS allele. Design: Control subjects from ovarian cancer case-control studies participating in the international Ovarian Cancer Association Consortium. The majority of controls are drawn from population-based studies. Setting: An international ovarian cancer consortium including studies from Australia, Europe, and the United States. Patient(s): Five thousand eight hundred twelve white female controls, of whom 348 had endometriosis, from eight ovarian cancer case-control studies. Intervention(s): None. Main Outcome Measure(s): Genotypes for the +331C/T single nucleotide polymorphism and PROGINS allele and a history of endometriosis. Result(s): The occurrence of endometriosis was reduced in women carrying one or more copies of the +331 T allele (odds ratio = 0.65; 95% confidence interval: 0.43-0.98), whereas there was no association between the PROGINS allele and endometriosis (odds ratio = 0.94, 95% confidence interval 0.76-1.16). Conclusion(s): Additional studies of the +331C/T variant are warranted given the current finding and the equivocal results of previous studies. The +331 T allele has been shown to result in a reduced progesterone (P) receptor A to P receptor B ratio, and if the observed association with endometriosis is confirmed it would suggest that this ratio is important for this disease.
AB - Objective: To investigate the association between self-reported endometriosis and the putative functional promoter +331C/T single nucleotide polymorphism and the PROGINS allele. Design: Control subjects from ovarian cancer case-control studies participating in the international Ovarian Cancer Association Consortium. The majority of controls are drawn from population-based studies. Setting: An international ovarian cancer consortium including studies from Australia, Europe, and the United States. Patient(s): Five thousand eight hundred twelve white female controls, of whom 348 had endometriosis, from eight ovarian cancer case-control studies. Intervention(s): None. Main Outcome Measure(s): Genotypes for the +331C/T single nucleotide polymorphism and PROGINS allele and a history of endometriosis. Result(s): The occurrence of endometriosis was reduced in women carrying one or more copies of the +331 T allele (odds ratio = 0.65; 95% confidence interval: 0.43-0.98), whereas there was no association between the PROGINS allele and endometriosis (odds ratio = 0.94, 95% confidence interval 0.76-1.16). Conclusion(s): Additional studies of the +331C/T variant are warranted given the current finding and the equivocal results of previous studies. The +331 T allele has been shown to result in a reduced progesterone (P) receptor A to P receptor B ratio, and if the observed association with endometriosis is confirmed it would suggest that this ratio is important for this disease.
KW - Endometriosis
KW - PROGINS
KW - ovarian cancer
KW - progesterone receptor
UR - http://www.scopus.com/inward/record.url?scp=78650417362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650417362&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2010.06.059
DO - 10.1016/j.fertnstert.2010.06.059
M3 - Article
C2 - 20719308
AN - SCOPUS:78650417362
SN - 0015-0282
VL - 95
SP - 40
EP - 45
JO - Fertility and sterility
JF - Fertility and sterility
IS - 1
ER -